EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Splice-Modulating Antisense Oligonucleotides as Therapeutics for Inherited Metabolic Diseases

Suxiang Chen, Saumya Nishanga Heendeniya, Bao T Le, Kamal Rahimizadeh, Navid Rabiee, Qurat Ul Ain Zahra, Rakesh N Veedu

BioDrugs · 2024-03 · 38 (2) · 177-203

DOI: 10.1007/s40259-024-00644-7 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift BioDrugs, online erschienen am 22.01.2024. Verfasst von Suxiang Chen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Molecular Medicine and Innovative Therapeutics, Health Futures Institute, Murdoch University, Murdoch, WA, 6150, Australia. Hauptthemen laut MEDLINE: Metabolic Diseases, Oligonucleotides, Antisense. Die Arbeit wurde bisher 79-mal zitiert (Crossref) und nennt 261 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Murdoch University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Metabolic DiseasesOligonucleotides, AntisenseHumansUnited States

Substanzen

Oligonucleotides, Antisense

Autor:innen und Institutionen

  • Centre for Molecular Medicine and Innovative Therapeutics, Health Futures Institute, Murdoch University, Murdoch, WA, 6150, Australia.
  • Precision Nucleic Acid Therapeutics, Perron Institute for Neurological and Translational Science, Nedlands, WA, 6009, Australia.
  • ProGenis Pharmaceuticals Pty Ltd, Bentley, WA, 6102, Australia.
  • Centre for Molecular Medicine and Innovative Therapeutics, Health Futures Institute, Murdoch University, Murdoch, WA, 6150, Australia. r.veedu@murdoch.edu.au.
  • Precision Nucleic Acid Therapeutics, Perron Institute for Neurological and Translational Science, Nedlands, WA, 6009, Australia. r.veedu@murdoch.edu.au.
  • ProGenis Pharmaceuticals Pty Ltd, Bentley, WA, 6102, Australia. r.veedu@murdoch.edu.au.

Förderung

  • Murdoch University

Zitieren

APA

Chen, S., Heendeniya, S. N., Le, B. T., Rahimizadeh, K., Rabiee, N., Zahra, Q. U. A., & Veedu, R. N. (2024). Splice-Modulating Antisense Oligonucleotides as Therapeutics for Inherited Metabolic Diseases. BioDrugs, 38(2), 177-203. https://doi.org/10.1007/s40259-024-00644-7

Vancouver

Chen S, Heendeniya SN, Le BT, Rahimizadeh K, Rabiee N, Zahra QUA, et al. Splice-Modulating Antisense Oligonucleotides as Therapeutics for Inherited Metabolic Diseases. BioDrugs. 2024;38(2):177-203. doi:10.1007/s40259-024-00644-7

BibTeX
@article{Chen2024,
  author = {Chen, Suxiang and Heendeniya, Saumya Nishanga and Le, Bao T and Rahimizadeh, Kamal and Rabiee, Navid and Zahra, Qurat Ul Ain and Veedu, Rakesh N},
  title = {Splice-Modulating Antisense Oligonucleotides as Therapeutics for Inherited Metabolic Diseases},
  journal = {BioDrugs},
  year = {2024},
  volume = {38},
  number = {2},
  pages = {177--203},
  doi = {10.1007/s40259-024-00644-7}
}
Kostenlos starten →